08 Jun Treating Metastatic Cervical Cancer With HPV-Targeted TILs
MedicalResearch: What are the main findings of the study?
Dr. Hinrichs: Objective tumor regression occurred in 3/9 patients with metastatic cervical cancer. Two responses were complete and are ongoing 22 and 15 months after treatment with a single infusion of T cells targeting the HPV oncoproteins.
MedicalResearch: Were any of the findings unexpected?
Dr. Hinrichs: The findings were unexpected in that durable, complete responses of metastatic cervical cancer to any treatment is unusual.
MedicalResearch: What should clinicians and patients take away from your report?
Dr. Hinrichs: There is a clinical trial for metastatic cervical cancer open at the NIH Clinical Center, and it has shown promising early results, but further study is needed.
MedicalResearch: What recommendations do you have for future research as a result of this study?
Dr. Hinrichs: We are continuing this study to better define the response rate to the treatment. We are also studying the same approach in non-cervical HPV+ cancers such as oropharyngeal and anal malignancies.
Abstract presented at the 2014 ASCO Meeting
HPV-targeted tumor-infiltrating lymphocytes for cervical cancer.
Christian S. Hinrichs, Sanja Stevanovic, Lindsey Draper, Robert Somerville, John Wunderlich, Nicholas P. Restifo, Richard Sherry, Phan Q Giao, Udai S. Kammula, James C. Yang, Steven A. Rosenberg; National Cancer Institute, Bethesda, MD; Surgery Branch, National Cancer Institute, Bethesda, MD
Abstract No: LBA3008